	US 11,981,967 B2
	Engineering AAV
Kyle McGovern, Richmond, CA (US); and David S. Ojala, Richmond, CA (US)
Assigned to Sangamo Therapeutics, Inc., Richmond, CA (US)
Filed by SANGAMO THERAPEUTICS, INC., Richmond, CA (US)
Filed on Apr. 24, 2020, as Appl. No. 16/858,489.
Claims priority of provisional application 62/939,094, filed on Nov. 22, 2019.
Claims priority of provisional application 62/915,386, filed on Oct. 15, 2019.
Claims priority of provisional application 62/839,421, filed on Apr. 26, 2019.
Prior Publication US 2020/0370137 A1, Nov. 26, 2020
Int. Cl. C12N 15/86 (2006.01); A61K 48/00 (2006.01); C07K 7/08 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 7/01 (2006.01); C12Q 1/6897 (2018.01); C40B 20/04 (2006.01)

CPC C12Q 1/6897 (2013.01) [C07K 7/08 (2013.01); C12N 15/86 (2013.01); C40B 20/04 (2013.01); C12N 2750/14111 (2013.01); C12Q 2563/185 (2013.01)]

20 Claims

1. An AAV capsid protein comprising at least 4 contiguous amino acids of an amino acid sequence set forth in any one of SEQ ID NO: 1-32 or at least 4 contiguous amino acids of an amino acid sequence set forth in any one of SEQ ID NO: 68-110.